Overview

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

Status:
Completed
Trial end date:
2014-06-12
Target enrollment:
Participant gender:
Summary
This study is designed to assess the efficacy and safety of etelcalcetide compared with placebo in the treatment of SHPT in patients with chronic kidney disease (CKD) receiving hemodialysis.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen